Published in AIDS on April 24, 2013
Generalizability and scalability of HIV 'treatment as prevention'. AIDS (2013) 1.39
How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS One (2014) 1.20
Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. PLoS One (2015) 1.15
Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. Pharmacoeconomics (2015) 0.83
The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS (2015) 0.82
HIV testing behaviors and attitudes among community recruited methamphetamine users in a South African township. AIDS Behav (2015) 0.81
Treatment as prevention--where next? Curr HIV/AIDS Rep (2014) 0.78
Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China. PLoS One (2016) 0.75
Gonadal function and reproductive health in women with human immunodeficiency virus infection. Endocrinol Metab Clin North Am (2014) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med (1965) 40.52
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep (2006) 11.08
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Tuberculosis. Lancet (2011) 8.07
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 7.72
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Invited commentary: ecologic studies--biases, misconceptions, and counterexamples. Am J Epidemiol (1994) 5.19
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS (2008) 2.91
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev (2011) 2.52
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet (2012) 2.41
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS (2010) 2.33
Use of the community viral load as a population-based biomarker of HIV burden. AIDS (2012) 2.31
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2011) 2.07
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
HIV treatment as prevention: to be or not to be? J Acquir Immune Defic Syndr (2010) 1.59
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
Abstinence-only programs for HIV infection prevention in high-income countries. Cochrane Database Syst Rev (2007) 1.52
HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr (2010) 1.47
HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact. Science (2011) 1.36
'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS (2008) 1.35
Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc (2011) 1.31
HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med (2012) 1.29
Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc (2011) 1.22
HIV treatment as prevention: issues in economic evaluation. PLoS Med (2012) 1.10
Condom effectiveness: where are we now? Sex Health (2012) 1.10
Prevalence of treatment optimism-related risk behavior and associated factors among men who have sex with men in 11 states, 2000-2001. AIDS Behav (2007) 1.04
Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr HIV Res (2005) 1.01
HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl (2009) 1.01
Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev (2011) 0.91
The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model. PLoS One (2012) 0.90
Implications of the Henan Province report on the treatment as prevention debate. J Acquir Immune Defic Syndr (2011) 0.83
Mortality of HIV-infected patients in low-income countries. Lancet (2006) 0.80
HIV-2 down, HIV-1 to go? Understanding the possibilities of treatment as prevention. Lancet Infect Dis (2011) 0.80
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PLoS Med (2007) 7.94
The social structural production of HIV risk among injecting drug users. Soc Sci Med (2005) 7.78
Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis (2012) 7.53
An open letter to The BMJ editors on qualitative research. BMJ (2016) 7.49
Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis (2012) 7.12
Protection against persistence of hepatitis C. Lancet (2002) 5.94
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis (2010) 4.19
Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. Subst Use Misuse (2006) 4.01
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
HIV prevalence, risks for HIV infection, and human rights among men who have sex with men (MSM) in Malawi, Namibia, and Botswana. PLoS One (2009) 3.68
Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend (2005) 3.67
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence. J Urban Health (2006) 3.51
Prevalence and correlates of HIV infection among female sex workers in 2 Mexico-US border cities. J Infect Dis (2008) 3.48
Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Stigma, health care access, and HIV knowledge among men who have sex with men in Malawi, Namibia, and Botswana. AIDS Behav (2011) 3.27
Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol (2007) 3.22
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa. J Acquir Immune Defic Syndr (2004) 3.19
Improving tuberculosis control through public-private collaboration in India: literature review. BMJ (2006) 3.19
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
An integrated physical and genetic map of the rice genome. Plant Cell (2002) 3.07
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse (2006) 2.81
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
WHO's new HIV guidelines: opportunities and challenges. Lancet (2013) 2.69
Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis (2010) 2.62
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Population-based survey methods to quantify associations between human rights violations and health outcomes among internally displaced persons in eastern Burma. J Epidemiol Community Health (2007) 2.59
Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis (2005) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS (2002) 2.57
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS (2002) 2.54
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav (2008) 2.49
Tuberculosis among health care workers. Emerg Infect Dis (2011) 2.49
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction (2008) 2.46
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis (2008) 2.44
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am (2002) 2.41
Tuberculosis control in the era of HIV. Nat Rev Immunol (2005) 2.40
Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health (2008) 2.35
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol (2009) 2.34
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One (2008) 2.31
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29
Mortality rates in conflict zones in Karen, Karenni, and Mon states in eastern Burma. Trop Med Int Health (2006) 2.29
Threading the Needle--How to Stop the HIV Outbreak in Rural Indiana. N Engl J Med (2015) 2.26
Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet (2010) 2.26
The Academy of Medical Royal Colleges' statement on clinical research in the UK. Lancet (2009) 2.23
Comparison of sexual and drug use behaviors between female sex workers in Tijuana and Ciudad Juarez, Mexico. Subst Use Misuse (2006) 2.21
Why older people do not participate in leisure time physical activity: a survey of activity levels, beliefs and deterrents. Age Ageing (2004) 2.20
RNA editing in the human ENCODE RNA-seq data. Genome Res (2012) 2.18
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend (2006) 2.17
Whither or wither microbicides? Science (2008) 2.17
Modified social ecological model: a tool to guide the assessment of the risks and risk contexts of HIV epidemics. BMC Public Health (2013) 2.16
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr (2009) 2.15
Syringe possession arrests are associated with receptive syringe sharing in two Mexico-US border cities. Addiction (2007) 2.14
Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol (2012) 2.13